Why Aytu Bioscience (AYTU) will reach price target of $20

The co-founders of Aytu Bioscience (AYTU) has a remarkable track record in the bio industry, these two founders Joshua Disbrow and Jarrett Disbrow has built a previous bio giants Arbor Pharmaceuticals & Vyrix Pharmaceuticals .

Aytu Bioscience (AYTU) & Arbor Pharmaceuticals

Currently, Arbor Pharmaceuticals is led by a team of skilled pharmaceutical veterans, many of whom have experience as healthcare practitioners. Our people fully understand the pharmaceutical development process and value our products can bring to the lives of patients.

The Arbor team is now over 300 strong and has full knowledge and capabilities in pharmaceutical research and development, manufacturing, quality control and market commercialization. We work with numerous partners throughout the world for the licensing, manufacturing or development of our marketed and late stage pipeline products.

In 2010, investment group JW Asset Management acquired Arbor Pharmaceuticals. The Disbrow brothers remained with company through acquisition and grew corporate annual Net Revenues from $3MM to over $127MM; grew commercial employee base from 16 employees to over 150.

Aytu Bioscience (AYTU) & Vyrix Pharmaceuticals

Vyrix Pharmaceuticals was a spin-off of Ampio Pharmaceutical’s sexual dysfunction business.

The sexual dysfunction and enhancement market is expected to exhibit a CAGR of 8.7% over the forecast period (2018-2026).

Key players operating in the premature ejaculation treatment market include Regent Pacific Group Limited, Menarini Group, Furiex Pharmaceuticals, Inc., Absorption Pharmaceuticals, LLC, Ampio Pharmaceuticals, Inc., Aytu BioScience, NeuroHealing Pharmaceuticals Inc., and Dong-A Pharmaceutical Co., Ltd.

Conclusion: Can the Disbrow brothers continue with Aytu Bioscience?

They certainly can hence the $20+ price target, meanwhile, shares of Aytu Bioscience appear to be a very good investment option, with Wall Street analysts expecting its price to rise considerably in the next several months. The majority of the metrics point to this investment being highly attractive.

Looking for an easier way to beat the market? Get Money Signals straight to your phone with over 50% in profits! Join now!

Jay Lorrence
Jay Lorrence

Investor of 12 years and Managing Editor of Money Midnight, a news outlet focused on highly profitable investment ideas and bold underground research.

Articles: 233

Newsletter Updates

Enter your email address below to subscribe to our newsletter